Suraksha Diagnostic Ltd: Q1 Profit Surges 30%, New CFO Appointed

Standalone Profit: ₹12.58 crore
Consolidated Profit: ₹12.85 crore

Reader Takeaway: Strong profit growth driven by operations, but ongoing subsidiary dispute poses a watch point.

What just happened

Suraksha Diagnostic Ltd announced its financial results for the first quarter ended June 30, 2026. The company reported a significant jump in profitability on both standalone and consolidated bases.

Standalone revenue grew to ₹84.09 crore from ₹70.28 crore in Q1 FY26, a 19.6% increase. Standalone profit rose to ₹12.58 crore from ₹9.85 crore, a growth of 27.7%.

On a consolidated basis, revenue reached ₹87.65 crore, up from ₹72.59 crore a year ago, marking a 20.7% increase. Consolidated profit surged by 30.1% to ₹12.85 crore from ₹9.18 crore in Q1 FY26.

Additionally, the company announced the appointment of Mr. Dinesh Gupta as the new Chief Financial Officer (and Group CFO), effective August 24, 2026. Mr. Gupta brings over 14 years of financial experience.

Why this matters

The strong financial performance indicates healthy operational growth for Suraksha Diagnostic. The appointment of a new CFO signals a strengthening of its financial leadership team. However, an ongoing dispute with the Government of Meghalaya concerning a subsidiary, which has led to a provision of ₹0.81 crore, is a key area for investors to monitor.

The backstory

Suraksha Diagnostic is a diagnostic service provider. The company is undergoing arbitration proceedings related to a dispute with the Government of Meghalaya, which has impacted its step-down subsidiary. A provision has been made to account for this potential risk, though management remains optimistic about a favourable outcome.

What changes now

With the appointment of Mr. Dinesh Gupta, the company aims to bolster its financial strategy and management. The upcoming Annual General Meeting (AGM) on September 22, 2026, and the dividend record date of September 15, 2026, are procedural events for shareholders.

Risks to watch

The primary risk highlighted is the ongoing legal dispute with the Government of Meghalaya concerning a subsidiary. This has resulted in operational losses and a financial provision of ₹0.81 crore. The arbitration proceedings scheduled for August 21, 2026, are critical.

Peer comparison

While specific peer data is not provided in the filing, Suraksha Diagnostic's Q1 performance shows robust growth compared to the previous year, suggesting it is outperforming in a competitive diagnostic market.

Context metrics

• Q1 FY27 Consolidated Revenue: ₹87.65 crore
• Q1 FY27 Consolidated Profit: ₹12.85 crore
• Provision for Subsidiary Dispute: ₹0.81 crore
• New CFO Effective Date: 24 August 2026
• AGM Date: 22 September 2026

What to track next

Investors should closely follow the outcome of the arbitration proceedings concerning the Meghalaya subsidiary. Continued operational performance and management's effectiveness under the new CFO will also be key factors.